BusinessMinerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016By Nasdaq OMXNov 10, 2016, 1:30 PM UTC
BusinessMinerva Neurosciences Reports Third Quarter 2016 Financial Results and Business UpdatesBy Nasdaq OMXNov 3, 2016, 11:30 AM UTC
BusinessMinerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016By Nasdaq OMXOct 27, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in SchizophreniaBy Nasdaq OMXOct 26, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual MeetingBy Nasdaq OMXOct 13, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical ProgramsBy Nasdaq OMXSep 26, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016By Nasdaq OMXSep 2, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences Reports Fiscal 2015 Fourth Quarter and Year End Financial Results and Business UpdatesBy Nasdaq OMXMar 14, 2016, 11:30 AM UTC
